Optimizing PARPi in Ovarian Cancer: Practical Guidance on Current Clinical Management Strategies

Review the latest data and expert guidance on PARP inhibitors to enhance your treatment of ovarian cancer. This comprehensive program features decision support tools focused commentaries an expert analysis module and a downloadable slideset.

Share

Program Content

Activities

PARPi in Ovarian Cancer
How I Am Using PARP Inhibitors in the Care of Patients With Ovarian Cancer
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: May 02, 2019

Expires: April 30, 2020

ASCO 2019 Data on PARPi
PARP Inhibitors in Recurrent Ovarian Cancer: What’s New at ASCO 2019
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: June 24, 2019

Expires: June 22, 2020

PARPi Dosing and Safety
Dosing and Safety of PARP Inhibitors in Ovarian Cancer: Tips From My Clinic
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: August 27, 2019

Expires: August 25, 2020

QUADRA Trial Implications
My Thoughts on the Clinical Implications of the Expanded Indication for Niraparib
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: November 26, 2019

Expires: November 24, 2020

Activities

PARPi in Ovarian Cancer
Multidisciplinary Expert Insights and Guidance on Using PARP Inhibitors in Ovarian Cancer
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: September 25, 2019

Expires: September 23, 2020

Faculty

cover img faculity

Laura Alwan, PharmD, BCOP

Clinical Instructor
University of Washington School of Pharmacy
Oncology Clinical Pharmacist
Seattle, Washington

cover img faculity

Virginia Bayer, BSN, RN, OCN

Research Nurse Supervisor
Department of Gynecology Oncology
MD Anderson Cancer Center
Houston, Texas

cover img faculity

Robert E. Coleman, MD, FRCP

Professor and Honorary Consultant Medical Oncologist
Cancer Clinical Trials Centre
Academic Unit of Clinical Oncology
Weston Park Hospital
Sheffield, England

cover img faculity

Ursula Matulonis, MD

Chief, Division of Gynecologic Oncology
Brock-Wilson Faculty Chair
Dana-Farber Cancer Institute
Professor of Medicine
Harvard Medical School
Boston, Massachusetts

cover img faculity

Kathleen N Moore, MD, MS

Virginia Kerley Cade Chair in Developmental Therapeutics
Deputy Director
Cancer Therapeutics Co-Director
Stephenson Cancer Center at the University of Oklahoma
ASCO BOD
Oklahoma City, Oklahoma

Provided by

ProCE Banner

Supporters

Supported by independent educational grants from

Clovis Oncology

Tesaro